Seasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development
November 07 2016 - 4:15PM
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development
of sustained release drug products and technologies, announced that
Deb Jorn, a proven business development executive, has joined the
Company as Executive Vice President of Corporate and Commercial
Development, a newly created position reporting directly to Nancy
Lurker, pSivida’s President and Chief Executive Officer. Ms. Jorn’s
primary responsibilities will be to establish collaborations
leveraging pSivida’s unique technologies and finalizing an EU
partnership deal for the Company’s Durasert™ three-year uveitis,
which was formerly known as Medidur.
Ms. Jorn’s experience and expertise in corporate
licensing, M&A and alliance management helped her build US and
global pharmaceutical businesses across numerous therapeutic areas,
including ophthalmology. Most recently, she was EVP and Company
Chair at Valeant Pharmaceuticals and previously served as Chief
Marketing Officer at Bausch & Lomb. Earlier, Ms. Jorn was Group
VP of Womens’ Healthcare and Fertility at Schering Plough. She was
also at Johnson & Johnson as the Worldwide VP of Internal
Medicine and Early Commercial Input. She began her career at Merck
and for more than twenty years held roles of progressive
responsibility in a variety of functions including R&D,
regulatory, sales and marketing. Ms. Jorn holds a B.A. in
Biochemistry from Rutgers University and an MBA from New York
University’s Stern Graduate School of Business Administration.
"Deb has an impressive track record and her
knowledge of the ophthalmology market and her corporate licensing
and M&A experience greatly enhance our team’s capabilities,”
commented Ms. Lurker. “She is a proven leader who, in addition to
her corporate licensing and M&A experience has also brought
many iconic brands to market. I look forward to working with Deb as
we begin the early planning for our future branding and launch of
Durasert three-year uveitis in the EU and US.”
“I am very excited about pSivida’s sustained
release drug products. I believe my pharmaceutical experience and
successful track record in corporate licensing and M&A will
enable us to leverage pSivida’s unique delivery technologies and
prepare Durasert three-year uveitis product for launch,” commented
Ms. Jorn.
About pSivida Corp. pSivida
Corp. (www.psivida.com), headquartered in Watertown, MA, is a
leader in the development of sustained release drug technologies
for eye diseases. pSivida has developed three of only four
FDA-approved sustained-release treatments for back-of-the-eye
diseases. The most recent, ILUVIEN®, a micro-insert for diabetic
macular edema, licensed to Alimera Sciences, is currently sold in
the US and three EU countries. Retisert®, an implant for posterior
uveitis, is licensed to and sold by Bausch & Lomb. pSivida's
lead product candidate, Durasert micro-insert for posterior segment
uveitis being independently developed, is currently in pivotal
Phase 3 clinical trials. pSivida's pre-clinical development program
is focused on using its core platform technologies Durasert™ and
Tethadur™ to deliver drugs and biologics to treat wet and dry
age-related macular degeneration, glaucoma, osteoarthritis and
other diseases. To learn more about pSivida, please visit
www.psivida.com and connect on Twitter, LinkedIn, Facebook and
Google+.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made
in this release are forward-looking, and are inherently subject to
risks, uncertainties and potentially inaccurate assumptions. All
statements that address activities, events or developments that we
intend, expect or believe may occur in the future are
forward-looking statements. Some of the factors that could cause
actual results to differ materially from the anticipated results or
other expectations expressed, anticipated or implied in our
forward-looking statements include uncertainties with respect to:
our ability to obtain needed capital; our ability to achieve
profitable operations; potential declines in Retisert royalties;
fluctuations in our operating results; further impairment of our
intangible assets; our ability to obtain marketing approvals for
and successfully commercialize Durasert three-year uveitis for
posterior segment uveitis; performance by CROs, vendors and
investigators; timing of filing marketing approval applications for
Durasert three-year uveitis; acceptability of data to be filed in
support of Durasert three-year uveitis marketing applications;
maintenance of orphan designation for Durasert three-year uveitis,
potential off-label sales of ILUVIEN for posterior segment uveitis;
successful commercialization of, and receipt of revenues from,
ILUVIEN for DME; Alimera's ability to continue as a going concern;
the effect of pricing and reimbursement decisions on sales of
ILUVIEN for DME; consequences of fluocinolone acetonide side
effects; outcome of dispute with Alimera on commercialization
expenses; any exercise by Pfizer of its option with respect to the
latanoprost product; our ability to develop Tethadur to
successfully deliver large biologic molecules and develop products
using it; efficacy and future development of severe OA implant by
us; our ability to successfully develop product candidates,
initiate and complete clinical trials and receive regulatory
approvals; our ability to market and sell products; the success of
current and future license agreements; termination or breach of
current license agreements; effects of competition and other
developments affecting sales of products; market acceptance of
products; effects of guidelines, recommendations and studies;
protection of intellectual property and avoiding intellectual
property infringement; retention of key personnel; product
liability; industry consolidation; compliance with environmental
laws; manufacturing risks; risks and costs of international
business operations; effects of potential U.K. exit from the EU;
legislative or regulatory changes; volatility of stock price;
possible dilution; absence of dividends; and other factors
described in our filings with the SEC. You should read and
interpret any forward-looking statements in light of these risks.
Should known or unknown risks materialize, or should underlying
assumptions prove inaccurate, actual results could differ
materially from past results and those anticipated, estimated or
projected in the forward-looking statements. You should bear this
in mind as you consider any forward-looking statements. Our
forward-looking statements speak only as of the dates on which they
are made. We do not undertake any obligation to publicly update or
revise our forward-looking statements even if experience or future
changes makes it clear that any projected results expressed or
implied in such statements will not be realized.
Contact:
EVC Group
Michael Polyviou/Doug Sherk – Investors
mpolyviou@evcgroup.com; dsherk@evcgroup.com
212.850.6020; 415.652.9100
Thomas Gibson – Media
tom@tomgibsoncommunications.com
201-476-0322
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Sep 2023 to Sep 2024